02256.HK
Abbisko Cayman Limited
HKSE · Healthcare · Biotechnology · CN
HKD 8.77
−1.79%Year over year
Reported trailing growth
- Revenue
- -84.3%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +1799.8%
- EBITDA
- -27.4%
- EPS
- -61.9%
Three-year CAGR
- Revenue
- +459.3%
- EBITDA
- +420.2%
- EBIT
- +225.9%
- Net income
- +90.2%
- EPS
- +115.2%
- Free cash flow
- +463.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026